383 related articles for article (PubMed ID: 24334454)
1. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
Crose LE; Galindo KA; Kephart JG; Chen C; Fitamant J; Bardeesy N; Bentley RC; Galindo RL; Chi JT; Linardic CM
J Clin Invest; 2014 Jan; 124(1):285-96. PubMed ID: 24334454
[TBL] [Abstract][Full Text] [Related]
2. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
[TBL] [Abstract][Full Text] [Related]
3. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
4. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
5. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
[TBL] [Abstract][Full Text] [Related]
6. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.
Thalhammer V; Lopez-Garcia LA; Herrero-Martin D; Hecker R; Laubscher D; Gierisch ME; Wachtel M; Bode P; Nanni P; Blank B; Koscielniak E; Schäfer BW
Cancer Res; 2015 Jan; 75(1):98-110. PubMed ID: 25398439
[TBL] [Abstract][Full Text] [Related]
7. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
8. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
[TBL] [Abstract][Full Text] [Related]
9. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
10. P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.
Bharathy N; Suriyamurthy S; Rao VK; Ow JR; Lim HJ; Chakraborty P; Vasudevan M; Dhamne CA; Chang KT; Min VL; Kundu TK; Taneja R
J Pathol; 2016 Nov; 240(3):269-281. PubMed ID: 27453350
[TBL] [Abstract][Full Text] [Related]
11. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
[TBL] [Abstract][Full Text] [Related]
12. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis.
Marshall AD; Lagutina I; Grosveld GC
Cancer Res; 2011 Dec; 71(24):7471-80. PubMed ID: 22037868
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Jothi M; Mal M; Keller C; Mal AK
Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
[TBL] [Abstract][Full Text] [Related]
14. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.
Marshall AD; van der Ent MA; Grosveld GC
Mol Carcinog; 2012 Oct; 51(10):807-15. PubMed ID: 21882254
[TBL] [Abstract][Full Text] [Related]
15. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
16. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.
Dietz KN; Miller PJ; Iyengar AS; Loupe JM; Hollenbach AD
Int J Biochem Cell Biol; 2011 Jun; 43(6):936-45. PubMed ID: 21440083
[TBL] [Abstract][Full Text] [Related]
17. IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS).
Picchione F; Pritchard C; Lagutina I; Janke L; Grosveld GC
Carcinogenesis; 2011 Apr; 32(4):452-61. PubMed ID: 21177767
[TBL] [Abstract][Full Text] [Related]
18. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.
Dietz KN; Miller PJ; Hollenbach AD
Biochemistry; 2009 Dec; 48(49):11786-95. PubMed ID: 19904978
[TBL] [Abstract][Full Text] [Related]
20. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]